Using BRCA1-deficient human ovarian cancer cells, they showed that pretreating these cells with cisplatin before adding a challenging dose of cisplatin yielded diminished RF degradation compared to BRCA1-deficient cells not pretreated with cisplatin. Here, BRCA1 is linked to ovarian cancer.